GroPep reports double profits
22 August, 2005 by Helen SchullerAdelaide-based GroPep (ASX:GRO) has recorded pre-tax profit of AUD$3.1 million for the year ending 30 June 2005, an increase of more than 200 per cent over the $1 million reported last year.
Stem Cell Sciences to commercialise neural technology
18 August, 2005 by Helen SchullerBioTech Capital (ASX:BTC) investee Stem Cell Sciences has been awarded an exclusive license to a new patented technology to derive and grow neural stem cells.
NeuroDiscovery closes IPO
12 August, 2005 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
Solagran defends ASX query on cash position
09 August, 2005 by Helen SchullerBotanical therapeutics specialist Solagran (ASX:SLA) has defended its financial position, after receiving a 'please explain' from the Australian Stock Exchange.
Diosynth to manufacture Agenix' Thromboview
05 August, 2005 by Helen SchullerAgenix (ASX:AGX, NASDAQ:OTC:AGXLY) has signed a multi-million dollar contract with US company Diosynth Biotechnology to begin the process of manufacturing its ThromboView blood clot imaging product for phase III clinical trials and commercial sale.
Norwood Immunology patent granted for Russia
01 August, 2005 by Helen SchullerNorwood Immunology, a subsidiary of Norwood Abbey (ASX:NAL) has been granted a additional patent relating to its immunology technology for a number of Eurasian territories, including Russia.
Stem Cell Sciences granted US patents
29 July, 2005 by Ruth BeranBioTech Capital (ASX:BTC) investee Stem Cell Sciences (SCS) has been granted additional claims to the 'stem cell selection' patented technology by the US Patent and Trademark Office.
Stem cell support continues, but public understanding still basic
29 July, 2005 by Helen SchullerPublic support for the use of stem cells and gene therapies has increased in Australia, and support for cloning humans remains low, according to a survey conducted by commonwealth agency Biotechnology Australia.
Expert forum maps impediments to GM crops
25 July, 2005 by Helen SchullerOver 100 representatives from industry, researchers, farmers' organisations and government took part in the 'Meeting of the Minds' agbiotech forum in Canberra last week to accurately map out differences in positions relating to the introduction of new genetically modified (GM) crops.
US preclinical trials for Mesoblast's stem cells
22 July, 2005 by Ruth BeranMelbourne-based stem cell specialist Mesoblast (ASX:MSB) has entered into agreements with Colorado State University to perform preclinical dose-escalation trials of its universal donor adult stem cell technology for the treatment of long bone fractures, and a new indication, intervertebral spinal fusion.
Stem cells could help treat uterine prolapse
21 July, 2005 by Graeme O'NeillResearchers at Melbourne's Monash Medical Research Institute (MMRI) have identified a readily accessible source of adult mesenchymal stem cells in the lining of the uterus that could help repair uterine prolapse.
It's time for scientists to stand up on cloning
18 July, 2005 by Senator Ron BoswellScientists need to stand up and be counted in the review of cloning legislation to be undertaken by the Lockhart Committee, writes the leader of the National Party in the Senate, Senator Ron Boswell.
LabTech set to commercialise microbial streaking technology
15 July, 2005 by Helen SchullerSouth Australian technology company LabTech Systems (NSX: LTS) is poised to undertake commercialisation of its newly invented brush applicator for the automation of routine microbiology testing in pathology and science laboratories.
Drought tolerance gene identified in wheat
15 July, 2005 by Graeme O'NeillIn the nick of time, climatically speaking, an Australian National University research team has cloned a plant gene that could markedly increase water-use efficiency in major food crops, including cereals.
Stem Cell Sciences raises £6 million on AIM
14 July, 2005 by Ruth BeranDespite terrorist attacks in London last week, BioTech Capital (ASX:BTC) investee company Stem Cell Sciences has raised £6 million (approximately AUD$14 million) as part of its initial public offering and listing on London's Alternative Investment Market (AIM).
